Verona_Pharma_Dark_medium.jpg
Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference
August 29, 2022 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), announces that senior management will present a company overview at...
Verona_Pharma_Dark_medium.jpg
Verona Pharma strengthens commercialization leadership team
August 24, 2022 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Aug. 24, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona_Pharma_Dark_medium.jpg
Nuance Pharma receives Clearance to begin Pivotal Clinical Trials with Ensifentrine for COPD in China
August 19, 2022 02:46 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Aug. 19, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona_Pharma_Dark_medium.jpg
Verona Pharma plc Announces Closing of Upsized Underwritten Public Offering, Including Full Exercise of Underwriters’ Option to Purchase Additional ADSs
August 15, 2022 16:05 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Aug. 15, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona_Pharma_Dark_medium.jpg
Verona Pharma plc Announces Pricing of Upsized Underwritten Public Offering
August 10, 2022 20:22 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona_Pharma_Dark_medium.jpg
Verona Pharma plc Announces Proposed Underwritten Public Offering
August 09, 2022 16:16 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Aug. 09, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the “Company”), a clinical-stage biopharmaceutical company focused on respiratory...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Reports Second Quarter 2022 Financial Results and Provides Corporate Update
August 09, 2022 03:00 ET | Verona Pharma plc
Ensifentrine met primary and secondary endpoints of evaluating lung function in Phase 3 ENHANCE-2 trial for COPD Top-line Phase 3 ENHANCE-1 data expected around the end of 2022 ...
Verona_Pharma_Dark_medium.jpg
Verona Pharma Announces Ensifentrine Meets Primary Endpoint in Phase 3 ENHANCE-2 Trial for COPD
August 09, 2022 02:00 ET | Verona Pharma plc
Statistically significant improvements in key measures of lung function 42% reduction in rate of exacerbations over 24 weeks Well tolerated with safety results similar to placebo Conference call...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Announce Top-line Data from Phase 3 ENHANCE-2 Trial of Nebulized Ensifentrine for COPD
August 08, 2022 16:30 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., Aug. 08, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma” or the "Company"), a clinical-stage biopharmaceutical company focused on respiratory...
Verona_Pharma_Dark_medium.jpg
Verona Pharma to Report Second Quarter 2022 Financial Results and Provide Corporate Update
July 29, 2022 02:00 ET | Verona Pharma plc
LONDON and RALEIGH, N.C., July 29, 2022 (GLOBE NEWSWIRE) -- Verona Pharma plc (Nasdaq: VRNA) (“Verona Pharma”), a clinical-stage biopharmaceutical company focused on respiratory diseases, announces...